Don’t confuse zoledronic acid code with Zometa

Article Overview

This short article explains an upcoming billing/coding update involving zoledronic acid and distinguishes between a branded product used in urology and another product approved for a different clinical use. It is relevant to coders, billing staff, and urology practices that need to understand how the change affects drug reporting and effective dates without mixing up similar product names. The article gives a high-level overview of the products, their clinical contexts, and the timing of the new code.